The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry

被引:2
|
作者
Braune, Stefan [1 ]
Bluemich, Sandra [2 ]
Bruns, Carola [2 ]
Dirks, Petra [3 ]
Hoffmann, Jeanette [2 ]
Heer, Yanic [4 ]
Rouzic, Erwan Muros-Le [3 ]
Bergmann, Arnfin [1 ]
机构
[1] NeuroTransData, Neuburg An Der Donau, Germany
[2] Roche Pharm AG, Grenzach Wyhlen, Germany
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] PricewaterhouseCoopers PwC, Zurich, Switzerland
关键词
Primary progressive multiple sclerosis; Natural history; Retrospective study; Cohort studies; Quality of life; BURDEN; ONSET; MS;
D O I
10.1186/s12883-023-03273-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundPrimary progressive multiple sclerosis (PPMS) is characterised by gradual worsening of disability from symptom onset. Knowledge about the natural course of PPMS remains limited.MethodsPPMS patients from the German NeuroTransData (NTD) MS registry with data from 56 outpatient practices were employed for retrospective cross-sectional and longitudinal analyses. The cross-sectional analysis included a contemporary PPMS cohort with a documented visit within the last 2 years before index date (1 Jan 2021). The longitudinal analysis included a disease modifying therapy (DMT)-naive population and focused on the evolution of expanded disability status scale (EDSS) from the first available assessment at or after diagnosis within the NTD registry to index date. Outcome measures were estimated median time from first EDSS assessment to first 24-week confirmed EDSS & GE; 4 and & GE; 7. Besides EDSS change, the proportion of patients on disability pension were described over time.ResultsThe cross-sectional analysis included 481 PPMS patients (59.9% female, mean [standard deviation, SD] age 60.5 [11.5] years, mean [SD] EDSS 4.9 [2.1]). Estimated median time from first EDSS assessment after diagnosis to reach 24-week confirmed EDSS & GE; 4 for DMT-naive patients was 6.9 years. Median time to EDSS & GE; 7 was 9.7 years for 25% of the population. Over a decade mean (SD) EDSS scores increased from 4.6 (2.1) to 5.7 (2.0); the proportion of patients on disability pension increased from 18.9% to 33.3%.ConclusionsThis study provides first insights into the German NTD real-world cohort of PPMS patients. Findings confirm the steadily deteriorating course of PPMS accompanied by increasingly limited quality of life.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies - insights from the German NeuroTransData registry
    Hong, Ja Bin
    Israel-Willner, Heike
    Peikert, Andreas
    Schanbacher, Peter
    Tozzi, Viola
    Koechling, Monika
    Reuter, Uwe
    Raffaelli, Bianca
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [42] Time to re-evaluate the natural history of primary progressive multiple sclerosis? Findings from a longitudinal study, British Columbia, Canada
    Tremlett, H
    Paty, D
    Devonshire, V
    MULTIPLE SCLEROSIS, 2005, 11 : S105 - S106
  • [43] The lymphocyte subpopulation in patients with primary progressive multiple sclerosis and secondary progressive multiple sclerosis
    Belniak, Ewa
    Bojarska-Junak, Agnieszka
    Bartosik-Psujek, Halina
    Mitosek-Szewezyk, Krystyna
    Kulka, Malgorzata
    Stelmasiak, Zbigniew
    Rolinski, Jacek
    MULTIPLE SCLEROSIS, 2008, 14 : S116 - S116
  • [44] Hydroxychloroquine for Primary Progressive Multiple Sclerosis
    Koch, Marcus W.
    Kaur, Sharanjit
    Sage, Kayla
    Kim, Janet
    Levesque-Roy, Myriam
    Cerchiaro, Graziela
    Yong, Voon Wee
    Cutter, Gary R.
    Metz, Luanne M.
    ANNALS OF NEUROLOGY, 2021, 90 (06) : 940 - 948
  • [45] Diagnosis of primary progressive multiple sclerosis
    Montalban, X
    NEUROLOGICAL SCIENCES, 2004, 25 : S31 - S31
  • [46] Treatment of Primary Progressive Multiple Sclerosis
    Kantarci, Orhun
    SEMINARS IN NEUROLOGY, 2013, 33 (01) : 74 - 77
  • [47] Ocrelizumab for primary progressive multiple sclerosis
    Adler, Ai
    Knight, H.
    LANCET NEUROLOGY, 2019, 18 (09): : 816 - 817
  • [48] The pathology of primary progressive multiple sclerosis
    Brück, W
    Lucchinetti, C
    Lassmann, H
    MULTIPLE SCLEROSIS, 2002, 8 (02): : 93 - 97
  • [49] The diagnosis of primary progressive multiple sclerosis
    Wolinsky, JS
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 206 (02) : 145 - 152
  • [50] Neuropsychology of primary progressive multiple sclerosis
    Paes, R.
    Papais-Alvarenga, R.
    Vasconcelos, C.
    Negreiros, M. A.
    Landeira, J.
    JOURNAL OF NEUROLOGY, 2008, 255 : 82 - 82